Skip to content

WHWK WHWK Additional Paid-In Capital

Additional Paid-In Capital at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.77B+3.2%
OS Therapies logo
OS TherapiesOSTX
$66.72M+75.1%
Eli Lilly logo
Eli LillyLLY
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's additional paid-in capital?
WHWK (WHWK) reported additional paid-in capital of $491.63M in Q1 2026.
How has WHWK's additional paid-in capital changed year-over-year?
WHWK's additional paid-in capital increased by 2.1% year-over-year, from $481.36M to $491.63M.
What is the long-term trend for WHWK's additional paid-in capital?
Over 4 years (2021 to 2025), WHWK's additional paid-in capital has grown at a 15.1% compound annual growth rate (CAGR), from $279.09M to $489.44M.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.